GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma

Pallavi Madhiraju- November 28, 2023 0

GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More

Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma

Pallavi Madhiraju- May 28, 2023 0

Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based ... Read More

Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis

pharmanewsdaily- January 16, 2021 0

DARZALEX FASPRO FDA approval for AL amyloidosis : Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured approval from the US Food and Drug ... Read More

Janssen seeks EMA’s expanded approval for DARZALEX in AL amyloidosis

pharmanewsdaily- November 8, 2020 0

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) seeking the expanded approval ... Read More

Janssen, Amgen secure FDA approval for DKd regiment in multiple myeloma

pharmanewsdaily- August 23, 2020 0

DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have been granted an expanded approval from the ... Read More

CANDOR clinical trial results : Amgen’s Kyprolis extends PFS in multiple myeloma patients

pharmanewsdaily- September 13, 2019 0

CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with dexamethasone and Johnson & Johnson's Darzalex (daratumumab) ... Read More

Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic

pharmanewsdaily- September 23, 2018 0

Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients ... Read More

Janssen secures EC approval for daratumumab as new multiple myeloma therapy

pharmanewsdaily- September 1, 2018 0

The Janssen Pharmaceutical Companies of Johnson & Johnson have achieved a significant milestone with the European Commission's approval of Darzalex (daratumumab) for use as an ... Read More